TCA
BMY.RT

Transcend Capital Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Transcend Capital Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-302,773
Closed -$209K – 434
2020
Q4 		$209K Sell
302,773
-85,635
-22% -$182K 0.03% 349
2020
Q3 		$874K Buy
388,408
+24,733
+7% +$70.6K 0.16% 129
2020
Q2 		$1.3M Sell
363,675
-117,374
-24% -$423K 0.42% 69
2020
Q1 		$1.83M Sell
481,049
-46
-0% -$152 0.55% 54
2019
Q4 		$1.45M Buy
+481,095
New +$1.25M 0.39% 79

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Transcend Capital Advisors's BMY.RT Position: Q1 2021 in Review

Transcend Capital Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 302,773 shares — an estimated $209K sold.

Transcend Capital Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.83M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Transcend Capital Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Transcend Capital Advisors sold 302,773 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $209K.
  • Transcend Capital Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Transcend Capital Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.83M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Transcend Capital Advisors's 13F filing for Q1 2021, filed 12 May 2021.